What changed in InflaRx N.V.'s 2025 10-K compared to 2024?

Across the narrative sections we track, InflaRx N.V. (IFRX) added 0 paragraphs, removed 0, and edited 0 between the 2024 and 2025 10-K filings. The biggest movers are .

Where does this IFRX 10-K diff come from?

The source filings are InflaRx N.V.'s official 2024 and 2025 Form 6-K annual reports from SEC EDGAR. 10q10k.net parses each filing, aligns paragraphs by section (Item 1, 1A, 1C, 2, 3, 7, 7A), and highlights every added, removed and edited sentence side-by-side.

InflaRx N.V.IFRX财报

Nasdaq · 医疗保健 · 药物制剂

InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the development of novel anti-inflammatory therapies targeting the complement C5a pathway. Its pipeline addresses unmet medical needs for severe inflammatory diseases including autoimmune and rare inflammatory disorders, serving global patient populations.

What changed in InflaRx N.V.'s 6-K — 2024 vs 2025

No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.